Samarendra Harsh, Jones Keaton, Petrinic Tatjana, Silva Michael A, Reddy Srikanth, Soonawalla Zahir, Gordon-Weeks Alex
Medical Sciences Division, University of Oxford, Oxford, UK.
CRUK/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, UK.
Br J Cancer. 2017 Jun 27;117(1):124-135. doi: 10.1038/bjc.2017.134. Epub 2017 May 23.
CXCL12 (SDF1) is reported to promote cancer progression in several preclinical models and this is corroborated by the analysis of human tissue specimens. However, the relationship between CXCL12 expression and cancer survival has not been systematically assessed.
We conducted a systematic review and meta-analysis of studies that evaluated the association between CXCL12 expression and cancer survival.
Thirty-eight studies inclusive of 5807 patients were included in the analysis of overall, recurrence-free or cancer-specific survival, the majority of which were retrospective. The pooled hazard ratios (HRs) for overall and recurrence-free survival in patients with high CXCL12 expression were 1.39 (95% CI: 1.17-1.65, P=0.0002) and 1.12 (95% CI: 0.82-1.53, P=0.48) respectively, but with significant heterogeneity between studies. On subgroup analysis by cancer type, high CXCL12 expression was associated with reduced overall survival in patients with oesophagogastric (HR 2.08; 95% CI: 1.31-3.33, P=0.002), pancreatic (HR 1.54; 95% CI: 1.21-1.97, P=0.0005) and lung cancer (HR 1.37; 95% CI: 1.08-1.75, P=0.01), whereas in breast cancer patients high CXCL12 expression conferred an overall survival advantage (HR 0.5; 95% CI: 0.38-0.66, P<0.00001).
Determination of CXCL12 expression has the potential to be of use as a cancer biomarker and adds prognostic information in various cancer types. Prospective or prospective-retrospective analyses of CXCL12 expression in clearly defined cancer cohorts are now required to advance our understanding of the relationship between CXCL12 expression and cancer outcome.
据报道，在多种临床前模型中CXCL12（SDF1）可促进癌症进展，对人体组织标本的分析也证实了这一点。然而，CXCL12表达与癌症生存率之间的关系尚未得到系统评估。
我们对评估CXCL12表达与癌症生存率之间关联的研究进行了系统综述和荟萃分析。
在总体生存、无复发生存或癌症特异性生存分析中纳入了38项研究，共5807例患者，其中大多数为回顾性研究。CXCL12高表达患者的总体生存和无复发生存的合并风险比（HRs）分别为1.39（95%CI：1.17 - 1.65，P = 0.0002）和1.12（95%CI：0.82 - 1.53，P = 0.48），但研究之间存在显著异质性。按癌症类型进行亚组分析时，CXCL12高表达与食管胃癌（HR 2.08；95%CI：1.31 - 3.33，P = 0.002）、胰腺癌（HR 1.54；95%CI：1.21 - 1.97，P = 0.0005）和肺癌（HR 1.37；95%CI：1.08 - 1.75，P = 0.01）患者的总体生存降低相关，而在乳腺癌患者中，CXCL12高表达赋予总体生存优势（HR 0.5；95%CI：0.38 - 0.66，P < 0.00001）。
CXCL12表达的测定有可能用作癌症生物标志物，并为各种癌症类型提供预后信息。现在需要对明确界定的癌症队列中的CXCL12表达进行前瞻性或前瞻性 - 回顾性分析，以加深我们对CXCL12表达与癌症结局之间关系的理解。
